2C-tBu
2C-tBu, or 2C-t-Bu, also known as 4-tert-butyl-2,5-dimethoxyphenethylamine, is a serotonin receptor agonist and putative serotonergic psychedelic of the phenethylamine and 2C families.
The active dose of 2C-tBu in humans is >5mg orally per Daniel Trachsel and its duration is unknown. Initial tests with 7mg and with 10mg orally produced no psychedelic effects in humans, but instead induced a pronounced and long-lasting tiredness. It was hypothesized by Daniel Trachsel and colleagues that 2C-tBu might be a serotonin 5-HT2A receptor antagonist and might thereby be hypnotic, but it was instead shown to be an agonist in subsequent studies.
Pharmacology
Pharmacodynamics
2C-tBu is a potent serotonin 5-HT2A receptor agonist and also binds to the serotonin 5-HT2C receptor. The drug produces a robust head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It also produces hyperlocomotion in rodents.
Chemistry
Analogues
Analogues of 2C-tBu include 2C-Bu, 2C-iBu, 2C-sBu, and DOTB, among others.
History
2C-tBu was first described in the scientific literature by Daniel Trachsel and colleagues in 2013.
Canada
2C-tBu is a controlled substance in Canada under phenethylamine blanket-ban language.